Paradigm shift in neuroprotection by NMDA receptor blockade: Memantine and beyond
The DOI matches its Crossref record; 98 of the 98 references it cites were found in a registry or an index.
Abstract
Neuroprotective drugs tested in clinical trials, particularly those that block N-methyl-D-aspartate-sensitive glutamate receptors (NMDARs), have failed miserably in large part because of intolerable side effects. However, one such drug, memantine, was recently approved by the European Union and the US FDA for the treatment of dementia following our group's discovery of its clinically tolerated mechanism of action. Here, we review the molecular basis for memantine efficacy in neurological diseases that are mediated, at least in part, by overactivation of NMDARs, producing excessive Ca(2+) influx through the receptor's associated ion channel and consequent free-radical formation.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The discrepancy in ketamine IC50 values between these two studies might be explained by the concentration of agonist used (50 μM versus 1 mM glutamate), as higher agonist concentrations allow non-competitive antagonists, e.g. ketamine, to block more effectively due to a greater number of open channels”
From Mechanisms of ketamine and its metabolites as antidepressants (2022) · cites this paper as Lipton, 2006
Citations
Cites
Glutamate neurotoxicity and diseases of the nervous system
CHOI, D. (1988) · Neuron · doi:10.1016/0896-6273(88)90162-6 · Cited by 7,972 · cited 1×
“D-aspartate receptor channel blockers memantine, MRZ 2/579 and other amino-alkyl-cyclohexanes antagonise 5-HT(3) receptor currents in cultured HEK293 and N1E-115 cell systems in a non-competitive manner.”
BackgroundAlzheimer's Disease: Genes, Proteins, and Therapy
Selkoe, D. J. (2001) · Physiological Reviews · doi:10.1152/physrev.2001.81.2.741 · Cited by 6,063
Magnesium gates glutamate-activated channels in mouse central neurones
Nowak, L., Bregestovski, P., Ascher, P., Herbet, A., & Prochiantz, A. (1984) · Nature · doi:10.1038/307462a0 · Cited by 4,043
Glycine potentiates the NMDA response in cultured mouse brain neurons
Johnson, J. W., & Ascher, P. (1987) · Nature · doi:10.1038/325529a0 · Cited by 3,139 · cited 1×
“The NR2 family of NMDAR subunits contains a binding site for glutamate, the endogenous agonist, whereas the NR1 subunit binds glycin”
BackgroundVoltage-dependent block by Mg2+ of NMDA responses in spinal cord neurones
Mayer, M. L., Westbrook, G. L., & Guthrie, P. B. (1984) · Nature · doi:10.1038/309261a0 · Cited by 2,893
Excitatory Amino Acids as a Final Common Pathway for Neurologic Disorders
Epstein, F. H., Lipton, S. A., & Rosenberg, P. A. (1994) · New England Journal of Medicine · doi:10.1056/nejm199403033300907 · Cited by 2,658 · cited 1×
“kon Channel + MEM ↔ Channel–MEM (Blocked channel) (1)”
Self-citationMolecular diversity of glutamate receptors and implications for brain function
Nakanishi, S. (1992) · Science · doi:10.1126/science.1329206 · Cited by 2,543
Heteromeric NMDA receptors: molecular and functional distinction of subtypes
Monyer, H., Sprengel, R., Schoepfer, R., Herb, A., Higuchi, M., Lomeli, H., Burnashev, N., Sakmann, B., & Seeburg, P. H. (1992) · Science · doi:10.1126/science.256.5060.1217 · Cited by 2,541
Lipton, S. A., Choi, Y.-B., Pan, Z.-H., Lei, S. Z., Chen, H.-S. V., Sucher, N. J., Loscalzo, J., Singel, D. J., & Stamler, J. S. (1993) · Nature · doi:10.1038/364626a0 · Cited by 2,433
Self-citationNitric oxide mediates glutamate neurotoxicity in primary cortical cultures.
Dawson, V. L., Dawson, T. M., London, E. D., Bredt, D. S., & Snyder, S. H. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.14.6368 · Cited by 2,174
Research works printed but not linked: 5
- Chen, H. -S. V. & Lipton, S. A. in Post Genomic Drug Discovery Research (ed. Huang, Z.) (John Wiley & Sons, Hoboken, NJ (in the press).
- Navia, B. A., Yiannoutsos, C., Ellis, R., Schifitto, G., Nath, A., Shriver, S., Millar, L. & Lipton, S. A. Memantine may prevent further cognitive decline in subjects with AIDS Dementia Complex with detectable CSF HIV RNA. Neurology 64 (Suppl. 1), A247–A238 (2005).
- Lipton, S. A., Rayudu, P. V., Choi, Y. -B., Sucher, N. J. & Chen, H. -S. V. in Prog Brain Res. (eds Mize, V., Dawson, T. M., Dawson, M. & Friedlander, M.) 73–82 (Elsevier, Amsterdam, 1998).
- Káradóttir, R., Cavelier, P., Bergersen, L. H. & Atwell, D. NMDA receptors in oligodendrocyte physiology and pathology. Nature (in the press).
- Micu, I. et al. NMDA receptors mediate Ca accumulation in central nervous system myelin during chemical ischemia. Nature (in the press).
Cited by
Items 501–600 of 943
Conti, P., Amici, M. D., Roda, G., Pinto, A., Tamborini, L., Madsen, U., Nielsen, B., Bräuner‐Osborne, H., & Micheli, C. D. (2006) · Tetrahedron · doi:10.1016/j.tet.2006.12.066 · Cited by 17
Feng, H.-J., Botzolakis, E. J., & Macdonald, R. L. (2008) · Neuropharmacology · doi:10.1016/j.neuropharm.2008.08.010 · Cited by 19
“Indeed, sensitivity to the context of receptor activation, both in terms of exposure duration and agonist concentration, has previously been described for open-channel blockers of nicotinic acetylcholine and NMDA-type glutamate receptors (Ascher, et al., 1978; Marty, 1978; Lipton, 2006).”
BackgroundKálai, T., Petrlová, J., Balog, M., Aung, H. H., Voss, J. C., & Hideg, K. (2011) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2011.01.059 · Cited by 18
“As established in laboratory and clinical studies, reactive oxygen and nitrogen species represent major intermediary species in AD progression pathways that ultimately lead to neurodegeneration [10, 11].”
BackgroundMemantine strikes the perfect balance
Spada, A. R. L. (2009) · Nature Medicine · doi:10.1038/nm1209-1355 · Cited by 19
del Río‐Sancho, S., Serna-Jiménez, C. E., Sebastián-Morelló, M., Calatayud-Pascual, M. A., Balaguer-Fernández, C., Femenía‐Font, A., Kalia, Y. N., Merino, V., & López‐Castellano, A. (2016) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2016.11.038 · Cited by 17
Singh, P., & Talwar, P. (2017) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2017.08.001 · Cited by 17
Use of memantine to treat Alzheimer's disease
Gauthier, S. G. (2006) · Canadian Medical Association Journal · doi:10.1503/cmaj.1060168 · Cited by 17
Pan, L., Quan, W., Zhou, Y., Wang, Y., Zhang, H., & Liu, S. (2016) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2016.3284 · Cited by 16
“Previously reviewed studies have observed that NMDA receptors are upregulated in FTLD and suggest that aberrant glutamatergic neurotransmission and glutamate excitotoxicity mediating cellular dysfunction may be implicated in the pathogenesis of FTLD (10).”
Olivero, G., Vergassola, M., Cisani, F., Usai, C., & Pittaluga, A. (2019) · Molecular Neurobiology · doi:10.1007/s12035-019-1511-8 · Cited by 16
Kumar, N., Gupta, P., & Bansal, S. (2022) · Letters in Drug Design & Discovery · doi:10.2174/1570180819666220314144219 · Cited by 16
Nakanishi, N., Kang, Y., Tu, S., McKercher, S. R., Masliah, E., & Lipton, S. A. (2015) · Journal of Molecular Neuroscience · doi:10.1007/s12031-015-0651-1 · Cited by 17
“NitroMemantines not only act as channel blockers via their memantine moiety but also allosterically inhibit NMDAR activity via an adducted nitro group that reacts with redox modulatory sites on the receptor (Lipton 2006; Talantova et al. 2013).”
Self-citationJoe, N., Scott, V., & Brown, C. H. (2013) · Journal of Neuroendocrinology · doi:10.1111/jne.12121 · Cited by 19
Wesseling, J. F., & Pérez‐Otaño, I. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2014.3953 · Cited by 17
According to GOSPEL: Filling in the GAP(DH) of NO-Mediated Neurotoxicity
Nakamura, T., & Lipton, S. A. (2009) · Neuron · doi:10.1016/j.neuron.2009.06.013 · Cited by 17
“Stimulation of NMDA receptors triggers Ca2+ influx, which in turn activates neuronal NO synthase (nNOS) as well as the generation of ROS (Hara et al., 2005; Lipton, 2006) (Figure 1).”
BackgroundSelf-citationPre‐synaptic glutamate‐induced activation of DA release in the striatum after partial nigral lesion
Dzahini, K., Dentresangle, C., Cavorsin, M. L., Bertrand, A., Durieux, I., Savasta, M., & Leviel, V. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.06682.x · Cited by 16
“To further investigate whether GLU could be responsible for the striatal DA normalization, following the lesion chronic treatments were made using three substances known for their effects on GLU neurotransmission and recognized to partly counteract neurodegeneration (Lipton 2006; Lamanauskas and Nistri 2008).”
BackgroundMethodInfluentialZhao, Y., Dou, J., Luo, J., Li, W., Chan, H. H. N., Cui, W., Zhang, H., Han, R., Carlier, P. R., Zhang, X., et al. (2011) · Brain Research · doi:10.1016/j.brainres.2011.09.014 · Cited by 16
“However, increasing evidence shows that overstimulation of glutamate receptors of the N-methyl-D-aspartate (NMDA) subtype may be involved in the pathogenesis of this disease (Lipton, 2006; Parsons et al., 2007).”
BackgroundHusain, S. M., Heim, M. T., Schepmann, D., & Wünsch, B. (2009) · Tetrahedron Asymmetry · doi:10.1016/j.tetasy.2009.05.017 · Cited by 16
Syntheses and analytical characterizations of N‐alkyl‐arylcyclohexylamines
Wallach, J. V., Colestock, T., Cicali, B., Elliott, S. P., Kavanagh, P. V., Adejare, A., Dempster, N. M., & Brandt, S. D. (2015) · Drug Testing and Analysis · doi:10.1002/dta.1861 · Cited by 16
“Issues linked with clinical tolerability remain challenging for clinical development of this promising pharmacological class.([1,13,14])”
Koch, G., Jusko, W. J., & Schropp, J. (2017) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-016-9502-0 · Cited by 16
“Some examples without TMDD behavior are: (i) lithium inhibiting inositol monophosphutuse [21] for psychiatric medication, or (ii) memantine an NMDA receptor antagonist for Alzheimer’s disease [13].”
A pharmacological MRI assessment of dizocilpine (MK-801) in the 3-nitroproprionic acid-lesioned rat
Roberts, T. J., Williams, S., & Modo, M. (2008) · Neuroscience Letters · doi:10.1016/j.neulet.2008.07.090 · Cited by 16
Oligodendrocyte N-Methyl-d-aspartate Receptor Signaling: Insights into Its Functions
Cao, N., & Yao, Z. (2013) · Molecular Neurobiology · doi:10.1007/s12035-013-8408-8 · Cited by 19
Recent Biochemical Advances in White Matter Ischaemia
Alix, J. J. P. (2006) · European Neurology · doi:10.1159/000095543 · Cited by 18
“In the context of cell-specific neuroprotection, much optimism surrounded the progression of both NMDA and non-NMDA glutamate receptor antagonists into clinical trials several years ago, but results have been disappointing thus far. The development and subsequent approval of memantine, an uncompetitive NMDA receptor a…”
NMDA receptor antagonists: tools in neuroscience with promise for treating CNS pathologies
Köhr, G. (2007) · The Journal of Physiology · doi:10.1113/jphysiol.2007.130732 · Cited by 17
“Memantine’s unusual clinical tolerance may well reflect its low affinity binding to open channels and its relatively fast unblocking kinetics (Johnson & Kotermanski, 2006; Lipton, 2006).”
BackgroundDesign, synthesis, and evaluation of polyamine-memantine hybrids as NMDA channel blockers
Kumamoto, T., Nakajima, M., Uga, R., Ihayazaka, N., Kashihara, H., Katakawa, K., Ishikawa, T., Saiki, R., Nishimura, K., & Igarashi, K. (2017) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2017.12.021 · Cited by 16
In vivo evidence for functional NMDA receptor blockade by memantine in rat hippocampal neurons
Szegedi, V., Juhász, G., Parsons, C. G., & Budai, D. (2010) · Journal of Neural Transmission · doi:10.1007/s00702-010-0471-y · Cited by 16
“Memantine is used in the symptomatic therapy of moderate-to-severe Alzheimer’s disease and there is considerable evidence indicating that NMDA receptor blockade underlies its therapeutic effects in this indication (Lipton 2006; Parsons and Gilling 2007; Parsons et al. 2007; Rogawski and Wenk 2003; Schmitt 2005).”
BackgroundFu, H., Dou, J., Li, W., Luo, J., Li, K. C., Lam, C. S. C., Lee, N. T. K., Li, M., & Han, Y. (2007) · Neuropharmacology · doi:10.1016/j.neuropharm.2007.12.003 · Cited by 16
Yue, Y., Luo, Z., Liao, Z., Zhang, L., Liu, S., Wang, M., Zhao, F., Cao, C., Ding, Y., & Yue, S. (2019) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00392.2018 · Cited by 15
Mitsuoka, T., Hanamura, K., Koganezawa, N., Kikura‐Hanajiri, R., Sekino, Y., & Shirao, T. (2019) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2019.106583 · Cited by 16
“The excitotoxicity of NMDAR is a target for drug development toward a wide variety of neurodegenerative disorders, such as Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, multiple sclerosis, amyotrophic lateral sclerosis (ALS), neuropathic pain, glaucoma and vascular dementia (Couratier et al., 1996; L…”
BackgroundJung, D. H., Lee, J. H., Lee, H. J., Park, J. W., Jung, Y., Shin, H. K., & Choi, B. T. (2024) · Theranostics · doi:10.7150/thno.90779 · Cited by 16
“Anodal tDCS at the lesional site for early-stage stroke may promote cell death via tDCS-induced overactivation of NMDA glutamate receptors [11, 33].”
BackgroundUnveiling new secrets in Parkinson’s disease: The glycatome
Chegão, A., & Miranda, H. V. (2023) · Behavioural Brain Research · doi:10.1016/j.bbr.2023.114309 · Cited by 15
Kadernani, Y., Zindo, F. T., Kapp, E., Malan, S. F., & Joubert, J. (2014) · MedChemComm · doi:10.1039/c4md00244j · Cited by 15
Takayama, H., Yaegashi, Y., Kitajima, M., Han, X., Nishimura, K., Okuyama, S., & Igarashi, K. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.06.069 · Cited by 15
Ватаев, С. И., Zhabko, E. P., Lukomskaya, N. Y., Oganesyan, G. A., & Magazanik, L. G. (2010) · Neuroscience and Behavioral Physiology · doi:10.1007/s11055-010-9345-x · Cited by 15
“Memantine is virtually the only glutamate antagonist used in clinical practice which has sufficiently selective actions on NMDA-type receptors with relatively low levels of side effects [11, 22, 23 , 28].”
Memantine can relieve the neuronal impairment caused by neurotropic virus infection
Sun, L., Zhou, M., Liu, C., Tang, Y., Xiao, K., Dai, J., Gao, Z., Siew, L., Cao, G., Wu, X. Y., et al. (2019) · Journal of Medical Virology · doi:10.1002/jmv.25396 · Cited by 15
Hemimacropsia after medial temporo-occipital infarction
Park, M., Choi, K., Kim, J. S., Park, K., Kim, D.-S., Kim, H. J., & Jung, D.-S. (2006) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2006.100842 · Cited by 15
Vandame, D., Desmadryl, G., Becerril-Ortega, J., Teigell, M., Crouzin, N., Buisson, A., Privat, A., & Hirbec, H. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.04925.x · Cited by 15
Evaluation of effects of memantine on cerebral ischemia in rats
Aluçlu, M. U., Arslan, S., Açar, A., Güzel, A., Bahçeci, S., & Yaldız, M. (2008) · Neurosciences · doi:10.17712/1658-3183.1571 · Cited by 15
Chen, M., Jin, J., Bi, H., Zhang, Y., Sun, M., Li, X., & Wang, Y. (2025) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2025.104502 · Cited by 14
Qi, X., Lu, J., Huang, Z.-Y., Liu, Y., Cai, L.-B., Wen, X.-L., Song, X.-L., Xiong, J., Sun, P., Zhang, H., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.849498 · Cited by 14
“…numerous studies have shown that glutamatemediated excitotoxicity and the excessive activation of N-methylD-aspartate receptors (NMDARs), which represent the major ionotropic glutamate receptors responsible for excitotoxicity, significantly contribute to ischemic neuron death (Lipton, 2006).”
BackgroundToll-Like Receptor 4 Signaling in Neurons Mediates Cerebral Ischemia/Reperfusion Injury
Liu, L., Xu, T., Zhao, Z., Zhang, N., Li, J., & Chen, D. (2022) · Molecular Neurobiology · doi:10.1007/s12035-022-03122-9 · Cited by 15
“Immediately following ischemia, glutamate accumulates rapidly at synapses, which stimulates N-methyl-d-aspartate receptors (NMDARs) to induce a large amount of calcium (Ca2+) influx through the NMDAR channels, resulting in irreversible neuronal death [5, 6].”
BackgroundInfluentialAlhowikan, A. M., Elamin, N. E., Aldayel, S. S., AlSiddiqi, S. A., Alrowais, F. S., Hassan, W. M., El-Ansary, A. K., Alghamdi, F. A., & AL-Ayadhi, L. Y. (2023) · Brain Sciences · doi:10.3390/brainsci13111575 · Cited by 14
“This explanation can find support by considering the fact that NMDA receptor antagonists reduce channel permeability and inhibit Ca 2+ influx, providing neuroprotection, amending glutamate excitotoxicity, and perhaps ameliorating hyperactivity symptoms [44,49].”
BackgroundRetour aux sources: defining the structural basis of glutamate receptor activation
Dawe, G. B., Aurousseau, M. R. P., Daniels, B. A., & Bowie, D. (2014) · The Journal of Physiology · doi:10.1113/jphysiol.2014.277921 · Cited by 16
“…is expected to have a significant impact in the long term, as we start to unravel how iGluRs are implicated in several prominent CNS disorders (Bowie, 2008) and continue the rational design of therapeutic compounds (Lipton, 2006; Sanacora et al. 2008; Santangelo et al. 2012; Pirotte et al. 2013).”
BackgroundSimulation of ligand dissociation kinetics from the protein kinase PYK2
Spiriti, J. M., Noé, F., & Wong, C. F. (2022) · Journal of Computational Chemistry · doi:10.1002/jcc.26991 · Cited by 14
Synthesis and NMDA receptor affinity of fluorinated dioxadrol analogues
Banerjee, A., Schepmann, D., & Wünsch, B. (2010) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2010.04.002 · Cited by 14
Human serine racemase is allosterically modulated by NADH and reduced nicotinamide derivatives
Bruno, S., Marchesani, F., Dellafiora, L., Margiotta, M., Faggiano, S., Campanini, B., & Mozzarelli, A. (2016) · Biochemical Journal · doi:10.1042/bcj20160566 · Cited by 17
Pharmacological and Electrophysiological Characterization of Novel NMDA Receptor Antagonists
Leiva, R., Phillips, M. B., Turcu, A. L., Gratacòs‐Batlle, E., León-García, L., Sureda, F. X., Soto, D., Johnson, J. W., & Vázquez, S. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00154 · Cited by 14
“than dizocilpine, have been proposed to be a major determinant of clinical tolerability.(29,33-34) An”
Medications and fall risk: a case–control study in nursing home residents in Japan
Park, H., Satoh, H., Miki, A., Maki, H., Asai, K., Shiraishi, A., Urushihara, H., & Sawada, Y. (2019) · Aging Clinical and Experimental Research · doi:10.1007/s40520-019-01265-9 · Cited by 16
Targeting Synaptic NMDA Receptor Co-agonism as a Therapy for Alzheimer’s Disease?
Hardingham, G. E. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2020.02.009 · Cited by 15
Lambert, L. J., Grotegut, S., Celeridad, M., Gosalia, P., Backer, L. J. S. D., Bobkov, A. A., Salaniwal, S., Chung, T. D. Y., Zeng, F., Pass, I., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094417 · Cited by 15
“The FDA has approved four drugs to treat the cognitive deficits in AD [12].”
BackgroundValeš, K., Rambousek, L., Holubová, K., Svoboda, J., Bubeníková‐Valešová, V., Chodounská, H., Vyklický, L., & Stuchlík, A. (2012) · Behavioural Brain Research · doi:10.1016/j.bbr.2012.07.020 · Cited by 14
Perlovich, G. L., Ryzhakov, A. M., Tkachev, V. V., & Proshin, A. N. (2014) · CrystEngComm · doi:10.1039/c4ce02076f · Cited by 14
Giulietti, A., Vignini, A., Nanetti, L., Mazzanti, L., Primio, R. D., & Salvolini, E. (2015) · Current Neuropharmacology · doi:10.2174/1570159x13666150928155321 · Cited by 19
“Other than AchE inhibitors, in 2003 FDA accepted thelow to moderate affinity uncompetitive N-methyl-d-aspartate (NMDA) receptor antagonistmemantine [100, 101] with similar effects on the management of disease progression (Fig.”
BackgroundThe Role of Protein S-Nitrosylation in Protein Misfolding-Associated Diseases
Ju, Y.-J., Lee, H.-W., Choi, J.-W., & Choi, M.-S. (2021) · Life · doi:10.3390/life11070705 · Cited by 14
“Several neurodegenerative diseases exhibit excessive production of ROS, including superoxide anions (O2•−) and reactive nitrogen species (RNS), including NO [42,43].”
BackgroundWu, S., Huang, H.-C., Yeh, C.-C., Yang, W.-H., & Lo, Y. (2011) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2011.01.066 · Cited by 14
“LaCl3 was reported to suppress capacitative Ca entry [23] and to inhibit the amplitude of IMEP [6,7], while MEM is a non-competitive antagonist of NMDA receptor [11].”
BackgroundNovel NMDA-receptor antagonists ameliorate vanadium neurotoxicity
Ladagu, A. D., Olopade, F. E., Folarin, O. R., Elufioye, T. O., Wallach, J. V., Dybek, M. B., Olopade, J. O., & Adejare, A. (2020) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-020-01882-6 · Cited by 13
“These second-generation compounds also take advantage of the fact that those NMDA receptor modulatory sites, including their ion channels, could be potentially used for safe but effective clinical intervention (Lipton 2004, 2006).”
BackgroundZambrano, P., Suwalsky, M., de Villena, F. P., Jemioła‐Rzemińska, M., & Strzałka, K. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.12.111 · Cited by 13
“On the other hand, memantine has a three-ring structure with a b ridgehead amine group that is protonated under physiological conditions carrying a positive charge (-NH3 ), and has two methyl side groups [6].”
BackgroundOkamoto, S., Prikhodko, O., Piña-Crespo, J., Adame, A., McKercher, S. R., Brill, L. M., Nakanishi, N., Oh, C.-K., Nakamura, T., Masliah, E., et al. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.03.029 · Cited by 13
“1a,b) (Chen and Lipton, 1997; Chen et al., 1992; Lipton, 2006; Xia et al., 2010).”
BackgroundMethodSelf-citationTrastorno límite de la personalidad (TLP): características, etiología y tratamiento
Morales, N. I. N., Sancho, M., Martínez, B. G., & Rahola, J. G. (2019) · Psiquiatría Biológica · doi:10.1016/j.psiq.2019.10.001 · Cited by 16
Castagna, A., Manzo, C., Fabbo, A., Lacava, R. V., Ruberto, C., & Ruotolo, G. (2021) · Clinical Drug Investigation · doi:10.1007/s40261-020-00996-2 · Cited by 13
Gilling, K. E., Jatzke, C., Wollenburg, C., Vanejevs, M., Kauss, V., Jirgensons, A., & Parsons, C. G. (2007) · Journal of Neural Transmission · doi:10.1007/s00702-007-0792-7 · Cited by 13
“…2002; Danysz and Parsons 2003; Rogawski Correspondence: Christopher G. Parsons, Merz Pharmaceuticals GmbH, Preclinical Research and Development, Eckenheimer Landstraße 100, 60318 Frankfurt, Deutschland e-mail: christopher.parsons@merz.de and Wenk 2003; Johnson and Kotermanski 2006; Lipton 2006).”
BackgroundFinn, R., Kovács, A., & Pearce, D. A. (2013) · Journal of Child Neurology · doi:10.1177/0883073813494480 · Cited by 13
“Excitotoxic cell death mediated by overactivation of NMDA receptors has been implicated in numerous neurodegenerative disorders, including Alzheimer’s disease, amyotrophic lateral sclerosis, Huntington’s disease, and Parkinson’s disease(13); and memantine has been found to be neuroprotective in cases of moderate to se…”
BackgroundOgura, M., Kikuchi, H., Shakespear, N., Suzuki, T., Yamaki, J., Homma, Y., Oshima, Y., & Homma, Y. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.10.008 · Cited by 13
Persico, A. M., Asta, L., Chehbani, F., Mirabelli, S., Parlatini, V., Cortese, S., Arango, C., & Vitiello, B. (2024) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2024.111176 · Cited by 16
Early Chronic Memantine Treatment-Induced Transcriptomic Changes in Wild-Type and Shank2-Mutant Mice
Yoo, Y.-E., Lee, S., Kim, W., Kim, H., Chung, C., Ha, S., Park, J., Chung, Y., Kang, H., & Kim, E. (2021) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2021.712576 · Cited by 16
“…stages, as supported by the fact that early, chronic (P7–21) treatment with memantine, a low-affinity uncompetitive antagonist of extrasynaptic NMDARs (Lipton, 2006) with beneficial effects on various brain disorders, including Alzheimer’s disease (Matsunaga et al., 2015; Folch et al., 2018),…”
BackgroundChang, C.-H., Liu, C., Chen, S.-J., & Tsai, H. (2021) · Scientific Reports · doi:10.1038/s41598-021-02040-5 · Cited by 12
Russell, T., Gangotia, D., & Barry, G. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113850 · Cited by 12
Medical countermeasures to WMDs: Defence research for civilian and military use
Hamilton, M. G., & Lundy, P. M. (2006) · Toxicology · doi:10.1016/j.tox.2006.08.034 · Cited by 12
Hoeller, A. A., Costa, A. P., Bicca, M. A., MATHEUS, F. C., Lach, G., Spiga, F., Lightman, S. L., Walz, R., Collingridge, G. L., Bortolotto, Z. A., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0147293 · Cited by 13
“Several high-affinity NMDAR antagonists present efficacy on receptor blockade but also toxicity and side effects [73, 74].”
BackgroundAllosteric Modulators of Potential Targets Related to Alzheimer's Disease: a Review
Silva, G. M., Barcelos, M. P., Poiani, J. G. C., Hage-Melim, L. I. D. S., & da Silva, C. H. T. D. P. (2019) · ChemMedChem · doi:10.1002/cmdc.201900299 · Cited by 12
Studies on the interaction of NMDA receptor antagonist memantine with cell membranes: A mini-review
Zambrano, P., Suwalsky, M., Jemioła‐Rzemińska, M., & Strzałka, K. (2018) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2018.01.022 · Cited by 17
Xiong, X., Poulsen, M. H., Hussein, R. A., Nørager, N. G., & Strømgaard, K. (2014) · ChemMedChem · doi:10.1002/cmdc.201402278 · Cited by 13
Olsen, C. A., Witt, M., Franzyk, H., & Jaroszewski, J. W. (2006) · Tetrahedron Letters · doi:10.1016/j.tetlet.2006.11.074 · Cited by 12
Preskorn, S., Borges, S., & Flockhart, D. A. (2006) · Journal of Psychiatric Practice · doi:10.1097/00131746-200609000-00006 · Cited by 12
Singh, M. K., Fu, M., Han, S., Ranbhise, J. S., Choe, W., Kim, S. S., & Kang, I. (2025) · Cells · doi:10.3390/cells14151179 · Cited by 11
“Memantine, a non-competitive NMDAR inhibitor, is currently approved for the treatment of AD [22].”
Effect of memantine: A NMDA receptor blocker, on ethambutol-induced retinal injury
Abdel‐Hamid, A. A. M., Firgany, A. E. L., & Ali, E. (2015) · Annals of Anatomy - Anatomischer Anzeiger · doi:10.1016/j.aanat.2015.11.006 · Cited by 11
Recent strategies for drug development in fibromyalgia syndrome
Blumenthal, D. E., & Malemud, C. J. (2016) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2016.1207531 · Cited by 11
“Memantine is an N-methyl-D-aspartate receptor antagonist [24].”
Cortés‐Montero, E., Rodríguez-Muñoz, M., Sánchez‐Blázquez, P., & Garzón, J. (2021) · Molecular Neurobiology · doi:10.1007/s12035-020-02265-x · Cited by 12
Mechanisms of NMDA receptor inhibition by nafamostat, gabexate and furamidine
Zhigulin, A. S., & Barygin, O. I. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.174795 · Cited by 11
Hayn, L., & Koch, M. (2015) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2015.08.001 · Cited by 12
Prodrug approaches to reduce hyperexcitation in the CNS
Vytla, D., Combs‐Bachmann, R. E., Hussey, A. M., McCarron, S. T., McCarthy, D. S., & Chambers, J. J. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2011.11.007 · Cited by 12
Bhat, C., & Tilve, S. G. (2013) · Tetrahedron · doi:10.1016/j.tet.2013.10.082 · Cited by 11
Graef, J. D., Benson, L. C., Sidach, S. S., Wei, H., Lippiello, P. M., Bencherif, M., & Fedorov, N. B. (2012) · SLAS DISCOVERY · doi:10.1177/1087057112457414 · Cited by 11
“These properties made memantine appealing because they allowed it to attenuate highfrequency pathological activity without affecting normal synaptic transmission.(24) Typically, there are two different ways to measure inhibition via open channel block: (1) resting block (classical) and (2) use-dependent block after re…”
BackgroundBanerjee, A., Fröhlich, R., Schepmann, D., & Wünsch, B. (2010) · MedChemComm · doi:10.1039/c0md00017e · Cited by 11
Huang, Z., Wen, W., Wu, A., & Niu, L. (2017) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.7b00211 · Cited by 11
Long, X., Wang, S., Luo, Z., Zhang, X., & Xu, H. A. (2020) · World Journal of Psychiatry · doi:10.5498/wjp.v10.i7.150 · Cited by 11
Moreira, P., Matos, P., Figueirinha, A., Salgueiro, L., Batista, M. T., Branco, P. C., Cruz, M. T., & Pereira, C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158812 · Cited by 13
“Indeed, memantine, which was approved by FDA and EMA for the treatment of AD symptoms, is an uncompetitive NMDA receptor antagonist that blocks excitoxicity with minimal side effects due to the preservation of normal glutamatergic transmission [260].”
BackgroundAlzheimer's disease: still a perplexing problem
Chinthapalli, K. (2014) · BMJ · doi:10.1136/bmj.g4433 · Cited by 11
Altered Actions of Memantine and NMDA-Induced Currents in a New Grid2-Deleted Mouse Line
Kumagai, A., Fujita, A., Yokoyama, T., Nonobe, Y., Hasaba, Y., Sasaki, T., Itoh, Y., Koura, M., Suzuki, O., Adachi, S., et al. (2014) · Genes · doi:10.3390/genes5041095 · Cited by 11
“Unexpectedly, our efforts resulted in the observation of new phenotypes in our Grid2 deficient mice, which appeared as enhanced memantine susceptibility, which was likely mediated by dysfunctional NMDA receptors [1,2,45].”
BackgroundResultGamdzyk, M., Ziembowicz, A., Bratek, E., & Salińska, E. (2016) · Pharmacological Reports · doi:10.1016/j.pharep.2016.06.009 · Cited by 11
Receptor Targets in Alzheimer’s Disease Drug Discovery
Wallach, J. V., Colestock, T., & Adejare, A. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802810-0.00006-4 · Cited by 14
Wang, X., Chen, J., Wang, H., Yu, H. Q., Wang, C., You, J., Wang, P., Feng, C.-M., Xu, G., Wu, X., et al. (2017) · Journal of Molecular Neuroscience · doi:10.1007/s12031-017-0948-3 · Cited by 12
“FDA-recommended medication to treat Alzheimer disease (AD), is a noncompetitive NMDAR antagonist (Lipton, 2006).”
BackgroundRahim, M. A., Yoon, Y., Dimovasili, C., Shao, Z., Huang, Q., Zhang, E., Kezunovic, N., Chen, L., Schaffner, A., Huntley, G. W., et al. (2020) · Brain Communications · doi:10.1093/braincomms/fcaa100 · Cited by 11
“Neuronal exposure to toxic insults, including glutamate excitotoxicity, oxidative stress and ischaemia, however, is believed to play crucial roles in chronic neurodegenerative disorders such as Alzheimer disease and Huntington diseases (Choi, 1988, 1995; Mattson, 2003; Lipton, 2006).”
BackgroundCente, M., Mandakova, S., & Filipčík, P. (2009) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-009-9379-1 · Cited by 11
“…that high efflux of glutamate during synaptic transmission leads to the overstimulation of NMDA receptors, increased intracellular calcium levels (Lipton 2006; Bojarski et al. 2008) and consequent production of free radicals and mitochondrial damage (Dawson et al. 1991; Ward et al. 2000).”
BackgroundZhou, X., Patel, A. R., Perez, F. P., & Jurivich, D. A. (2008) · Translational research · doi:10.1016/j.trsl.2008.12.003 · Cited by 11
Guan, S., Li, Y., Xin, Y., Wang, D., Lu, P., Han, F., & Xu, H. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.176520 · Cited by 12
The impact of ketamine on cognitive outcomes in geriatric anesthesia: a comprehensive review
You, S., & Li, Z. (2025) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1594730 · Cited by 12
Review of anti-amyloid-beta (Aβ) monoclonal antibodies for the treatment of Alzheimer’s disease
Francis, E., Paylor, S., Van, C., Mathews, B., Sobhanian, M. J., Mansour, D. Z., Hennawi, G., & Brandt, N. (2025) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2025.2556122 · Cited by 13
“Concurrently, glutamatergic excitotoxicity, mediated by N-methyl-D-aspartate (NMDA) receptor overactivation and calcium dysregulation, contributes to neuronal apoptosis [33].”
Tencheva, A., Liu, R., Volkova, Т. V., Chayrov, R., Mitrev, Y., Štícha, M., Li, Y., Jiang, H., Li, Z., Stankova, I. G., et al. (2020) · Amino Acids · doi:10.1007/s00726-020-02914-4 · Cited by 12
“Memantine slows the cognitive decline associated with AD and represents a departure in AD therapy from previously developed medications that enhance cholinergic transmission (Lipton 2006; Schmitt 2005).”
Background15 Years of molecular simulation of drug-binding kinetics
Wong, C. F. (2023) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2023.2264770 · Cited by 12
“Fast off rate plays a role in reducing its toxicity [12].”
BackgroundZhigulin, A. S., & Barygin, O. I. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242115685 · Cited by 11
“Memantine— a moderate affinity NMDA receptor open channel blocker—is used in Alzheimer’s dis‑ ease treatment [5].”
BackgroundMethod
Metadata
- Authors
- Lipton, S. A.
- Affiliations
- Sanford Burnham Prebys Medical Discovery Institute (US)
- Corresponding author
- Lipton, Stuart A.
- ORCID
- Lipton, Stuart A.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2006-01-20
- Volume
- 5
- Issue
- 2
- Pages
- 160-170
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W1981238903
- Cited by
- 909
- References
- 98
- Citations by year
- 2026: 39 · 2025: 31 · 2024: 32 · 2023: 31 · 2022: 40 · 2021: 41 · 2020: 51 · 2019: 42 · 2018: 36 · 2017: 40 · 2016: 48 · 2015: 51 · 2014: 47 · 2013: 48 · 2012: 52
- FWCI
- 5.57
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Keywords
- memantine, NMDA receptor antagonists, neuroprotection, Alzheimer's disease, dementia, glutamate excitotoxicity, calcium influx, free radicals, adverse drug reactions, clinical trial failure, NMDA receptor overactivation
- MeSH terms
- Animals, Humans, Memantine, Neurotoxins, Receptors, N-Methyl-D-Aspartate, Excitatory Amino Acid Antagonists, Neuroprotective Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.